Analysed LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ) News Sources
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions
07-04-2026
yahoo.com
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
24-03-2026
yahoo.com
Novo Nordisk (CPSE:NOVO B) Valuation Check As LX9851 Expands Its Obesity Drug Pipeline
23-03-2026
yahoo.com
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
23-03-2026
yahoo.com
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating
12-03-2026
yahoo.com
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
11-03-2026
yahoo.com
What is the current price of LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ)?
The current price of LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ) is $1.72.
LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ) since the previous trading day is $-0.04.
LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ) since the previous trading day is -2.2727%.
What is the most recent average sentiment score for LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ)?
The most recent average sentiment score for LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ)?
The most recent sentiment for LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ) is .
SEC-8K** Filing Available For LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.